ReproCELL Incorporated (4978) Q2 2025 earnings summary

Executive summary

• Revenue for the period ended June 30, 2024, was ¥1,320 million, up from ¥1,147 million year-over-year.

• Operating income increased to ¥104 million from ¥60 million year-over-year.

• Net income rose to ¥103 million compared to ¥70 million in the prior year.

• EPS improved to ¥1.14 from ¥0.71 year-over-year.

Financial highlights

• Gross profit reached ¥544 million, up from ¥404 million year-over-year.

• Total assets increased to ¥9,422 million from ¥9,052 million at the previous year-end.

• Equity ratio remained stable at 92.8%.

• Cash and cash equivalents stood at ¥2,605 million as of June 30, 2024.

• R&D expenses totaled ¥104 million, up from ¥60 million year-over-year.

Outlook and guidance

• Continued focus on iPS cell-related business and expansion of GMP-compliant manufacturing.

• Ongoing development of TIL (Tumor Infiltrating Lymphocyte) therapies and AI-driven pharmacology collaborations.

• Strategic alliances and investments in AI and biotherapeutics expected to drive future growth.